Intellia Therapeutics, Inc. (NTLA): Depreciation & Amortization
$9.77M
Year ended 2025-12-31
$9.08M
Trailing 12 months to 2026-06-30
+8.9%
3-year compound annual growth
+9.1%
5-year compound annual growth
+40.4%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.77M | -5.0% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $10.29M | +14.6% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $8.98M | +18.5% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $7.57M | +9.9% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $6.89M | +9.2% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $6.31M | +13.0% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $5.59M | +25.2% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $4.46M | +49.1% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $2.99M | +171.2% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $1.10M | +236.6% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $328.0K | n/a | 2018-03-14, From 2015-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $9.77M | -5.0% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $6.34M | -3.6% |
| Immucell Corp (ICCC) | 2025-12-31 | $2.78M | +2.0% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $112.0K | +21.7% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $53.70M | -12.3% |
| Neogen Corp (NEOG) | 2026-05-31 | $116.30M | -2.7% |
| Biomerica Inc (BMRA) | 2026-05-31 | $77.0K | -11.5% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $2.19M | +48.4% |
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $70.10M | +8.5% |
Compare NTLA, TKNO, ICCC, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗